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ABSTRACT 
Objective: Risk score models and the diagnosis of a metabolic syndrome are useful for cardiovascular (CV) risk pre- 
diction. The identification of individuals with high CV and metabolic risk is essential to provide appropriate prevention 
and therapy. The present study aims at clarifying whether these indicators are altered by a weight reduction programme. 
Additionally, which diagnostic tool has a better predictive value is examined. Method: One hundred and twenty over- 
weight and obese subjects aged 30 - 60 years were included in a 12-week weight reduction programme. The CV risk 
was assessed by means of German multiple-used risk charts (SCORE) at baseline and at the end of the trial. Further- 
more, the prevalence of the metabolic syndrome (three out of five risk factors) was quantified. Results: The initial 
prevalence of the metabolic syndrome was 63.3% (n = 76) and decreased to 41.7% (n = 50) by the end of the interven- 
tion. The SCORE also decreased significantly after twelve weeks (p < 0.001). The percentage of subjects at high risk 
(SCORE > 5%) was comparatively low (t0: 7.4%, n = 7; t12: 5.3%, n = 5). Conclusion: The weight reduction concept 
was applicable to improve the CV risk SCORE and decrease the prevalence of the metabolic syndrome. The CV 
10-year risk calculated using German risk charts (SCORE) probably underestimated the risk of CV diseases in this col- 
lective. In this case, the diagnosis of a metabolic syndrome is more meaningful than risk SCORE calculations. 
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1. Introduction 
Visceral obesity is a major risk factor for many serious 
conditions, including heart disease, type-2 diabetes, hy- 
pertension, stroke, and certain types of cancer [1-3]. Due 
to their common occurrence, these diseases form a clus- 
ter that has been termed metabolic syndrome [4]. Data 
from prospective population-based cohort studies have 
shown that obesity appeared to be the central feature of 
the metabolic syndrome [5-8]. Metabolic syndrome is an 
established instrument to identify subjects with increased 
cardiovascular (CV) morbidity and mortality [9]. On the 
other hand, risk predictions, such as the Framingham risk 
score [10], PROCAM score [11] and the SCORE of the 
European Society of Cardiology (ESC) [12,13], are also 
opportunities for global CV risk assessment. The specific 
risk tables for the German population, SCORE Deutsch- 
land, were designed within the framework of the Euro- 
pean Heartscore project and are intended for calculating 
the 10-year risk of fatal cardiovascular disease (CVD), 
including stroke, in men and women [13]. It has been 
shown that this SCORE is a widely used risk assessment 
tool in Germany and Europe [14]. Identification of high- 
risk individuals using risk predictions or criteria for the 
metabolic syndrome is essential to provide appropriate 
therapy.  
The first therapeutic step in lowering CV and meta- 
bolic risk should be weight reduction in combination 
with increased physical activity. Studies have shown that 
moderate weight loss and lifestyle intervention can sig- 
nificantly improve several aspects of the metabolic syn- 
drome [15-17]. *Funding: the study relevant to the subject of this article was funded by 
Certmedica International GmbH, Aschaffenburg, Germany. 
#Conflict of interest: the authors declared no conflict of interest. 
In this study, we determined the prevalence and char- 
acteristics of the metabolic syndrome in overweight and 
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obese individuals participating in a weight reduction pro- 
gramme. Furthermore, we examined the effects of weight 
loss on the components of the metabolic syndrome and a 
CV risk score. Additionally, we checked if the two risk 
calculation methods have a comparable significance. 
2. Material and Methods 
2.1. Study Population 
One hundred and twenty individuals (n = 59 men, n = 61 
women) participated in a 12-week weight loss pro- 
gramme at the Institute of Food Science and Human Nu- 
trition, Leibniz University Hannover, Germany. The trial 
protocol has been approved by an ethical committee and 
meets the standards of the Declaration of Helsinki. The 
clinical investigation was registered in the German 
Clinical Trials Register (DRKS) with the identification 
number DRKS00000325. Written informed consent was 
obtained from all participants. Further study information, 
detailed descriptions of the programme and first inter- 
vention results have already been published [18]. De- 
tailed information was collected from each patient at 
baseline and at the end of active weight loss. The exami- 
nations included anthropometric and blood pressure 
measurements, as well as a fasting blood sample. Body 
Mass Index (BMI) was calculated as weight (kg) divided 
by height squared (m2). Waist circumference (WC) was 
measured midway between the lowest rib margin and 
iliac crest with the tape measure all around the body in a 
horizontal position. Individuals having a WC beyond 88 
cm in women and 102 cm in men were classified as hav- 
ing a high WC [19]. Blood pressure was measured using 
a sphygmomanometer after a rest while the patients were 
seated. Readings were taken three times at intervals of 
three minutes. The mean value was calculated from this 
set of readings.  
2.2. Identification of the Metabolic Syndrome 
The criteria according to [20] were used to determine the 
presence of a metabolic syndrome. The diagnosis of 
metabolic syndrome was made if at least three out of five 
risk factors (WC ≥ 102 cm in men, and ≥ 88 cm in 
women; Triglycerides (TG) ≥ 150 mg/dl ≥ 1.7 mmol/l; 
HDL-C < 40 mg/dl < 1.03 mmol/l in men, and < 50 
mg/dl < 1.29 mmol/l in women: fasting glucose ≥ 100 
mg/dl ≥ 5.6 mmol/l; blood pressure ≥ 130 mmHg systolic 
and/or ≥ 85 mmHg diastolic) were present.  
2.3. SCORE Assessment 
The CV risk score assessment was calculated by using 
SCORE risk tables for the German population [13]. The 
SCORE calculation included gender, age, smoking status, 
systolic blood pressure (SBP), and total cholesterol/ 
HDL-cholesterol (TC/HDL-C) ratio. Younger people were  
excluded from this calculation as the risk charts provide 
age ≥ 40 years. Due to a consensus [13], a risk of a fatal 
CV event in ten years of >5% was classified as high risk, 
so that intensive monitoring and accurate treatment is 
normally indicated. 
2.4. Statistical Analysis 
Data were analysed using IBM® SPSS® Statistics version 
19.0. The results are presented as mean ± standard devia- 
tion (s.d.) for continuous variables and as number of 
subjects (n) and percentage (%), respectively, for cate- 
gorical variables. Differences between men and women, 
as well as between individuals with and without the 
metabolic syndrome were calculated using the Mann- 
Whitney U test. The changes in the parameters in com- 
parison with baseline were analysed using the Wilcoxon 
test. Spearman correlation coefficients were used to 
evaluate association between variables. The McNemar 
chi-square test was used for the comparison of frequen- 
cies. P-values < 0.05 were considered to be statistically 
significant. All 120 randomised subjects were assessed 
on the basis of the Intention-To-Treat (ITT) analysis. The 
output values were constantly adjusted in subjects with- 
out any further values after the baseline measurements 
(last observation carried forward). 
3. Results 
The basis of the present analysis is a sample of 120 par- 
ticipants from this interventional trial. The baseline 
characteristics are shown in Table 1. 
 
Table 1. Baseline characteristics of the study population (n 
= 120). 
Parameter Total study group 
Sex [m/f] 59/61 
Age [y] 46.8  7.2 
BMI [kg/m2] 32.1  2.0 
Prevalence Metabolic syndrome [%] 63.3 (n = 76) 
SCORE [%]a 1.88  0.19 
WC [cm] 106  8.0 
SBP [mmHg] 139  15 
DBP [mmHg] 94  11 
TC [mg/dl] 241  44.0 
HDL-C [mg/dl] 54.5  12.1 
TG [mg/dl] 174  117 
Glucose [mg/dl] 95.9  12.4 
Smoking [smoker/non-smoker]b 18/101 
an = 95, age > 40 years; bone invalid answer. 
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The average weight loss from baseline to twelve weeks 
in the study population was 4.5 ± 4.0 kg or 4.6% ± 3.9% 
of the initial body weight (p < 0.001). Weight reduction 
was significantly higher in men than in women (−5.4 ± 
4.6 kg vs. −3.4 ± 3.5 kg, p = 0.036). The BMI also de- 
creased significantly (−1.4 ± 1.2 kg/m2, p < 0.001) in the 
total study group after twelve weeks (data not shown). 
Further intervention results have been published else- 
where [18]. 
3.1. Prevalence of the Metabolic Syndrome and 
Changes during Intervention 
The initial prevalence of a metabolic syndrome (at least 
three out of five risk factors) was 63.3% (n = 76). Men 
had a statistically significant higher prevalence of the 
metabolic syndrome at baseline than women (n = 47 vs. n 
= 29, p < 0.001). Approximately 21.7% (n = 26) of indi- 
viduals had four defining components and 3.3% (n = 4) 
had all five components of the metabolic syndrome. The 
most frequent components of the metabolic syndrome at 
baseline were increased WC and hypertension. Addition- 
ally, the highest improvements during the intervention 
were seen in these components as well. The changes of 
prevalence were −17.5% (WC), −20% (blood pressure), 
−2.5% (HDL-C), −9.1% (TG), and −9.2% (fasting glu- 
cose). The prevalence of the single variables of the 
metabolic syndrome at baseline and after twelve weeks is 
shown in Figure 1.  
After twelve weeks, 41.7% (n = 50) of the subjects 
still had a metabolic syndrome. Subjects with the meta- 
bolic syndrome had statistically significant differences in 
parameters, such as age, WC, SBP, TC, TG, and glucose, 
compared with subjects without the metabolic syndrome 
at any time (Table 2).  
The prevalence of individuals with a metabolic syn- 
drome at baseline and even after twelve weeks was 
 
 
Figure 1. Prevalence of the single components of the meta- 
bolic syndrome at baseline and after twelve weeks (n = 120). 
38.3% (n = 46). A percentage of 25% (n = 30) had a 
metabolic syndrome at baseline and were without it at the 
end of the intervention. Forty of the individuals (33.3%) 
had no metabolic syndrome either at baseline or after 
twelve weeks, and four (3.3%) developed a metabolic 
syndrome during the intervention period. The difference 
between the number of improvements (n = 30) and the 
number of deteriorations (n = 4) was, according to the 
McNemar chi-square test, highly significant (p < 0.001). 
Differences in comparisons were clearly recognisable 
by looking at each component of the metabolic syndrome 
in subjects with various numbers of criteria. Parameters 
of the metabolic syndrome as a function of the number of 
criteria fulfilled are shown in Table 3. There was a trend 
towards increases in each factor in the subjects separated 
by the number of criteria for the metabolic syndrome, 
which was statistically significant in stepwise compari- 
son. 
The changes in body weight and BMI were signifi- 
cantly associated with the change in each variable of the 
metabolic syndrome (Table 4). There was also a statisti- 
cally significant correlation between the changes in 
weight and BMI with the changes in the CV risk 
SCORE.  
3.2. Cardiovascular Risk SCORE  
The SCORE assessment was limited to subjects ≥ 40 
years old. This subgroup of n = 95 individuals (n = 49 
men, n = 46 women) initially had a mean 10-year CV 
risk of 1.88% ± 0.19% (range: 0% - 11%). Smokers and 
non-smokers were in a ratio of 15:79, respectively (one 
invalid answer). The mean risk SCORE after the 12- 
week weight loss programme decreased significantly by 
−0.27% ± 0.64% (p < 0.001). This significant improve- 
ment was modest and could be seen in both men and 
women. The CV risk SCORE was statistically significant 
different between men and women both at the beginning 
and at the end of the observation period (t0: 2.4% ± 2.3% 
vs. 1.1% ± 1.0%, p < 0.001; t12: 2.0% ± 1.9% vs. 0.9% ± 
0.9%, p < 0.001). Components of the CV risk SCORE 
and the metabolic syndrome in the SCORE subgroup 
aged ≥ 40 years at baseline and at the end of the study are 
presented in Table 5. The differences of the risk SCORE 
between baseline and after twelve weeks had a low but 
significant association with the differences of BMI (r = 
0.247, p = 0.016) and body weight (r = 0.274, p = 0.007). 
There was also a significant inverse correlation between 
the difference of the risk SCORE between baseline and 
after twelve weeks and the baseline SCORE values (r = 
−0.437, p < 0.001). The higher the baseline SCORE was, 
the stronger SCORE decreased during intervention. Fur- 
ther associations were seen, as expected, between the 
hanges in SCORE and the changes in the integrated  c 
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Table 2. Description of individuals with and without the metabolic syndrome at baseline and after twelve weeks (n = 120). 
 Baseline  12 weeks  
Parameter With metabolic syndrome Without metabolic syndrome p
a With metabolic syndrome Without metabolic syndrome p
a 
N 76 44  50 70  
Sex [m/f] 47/29 12/32 <0.001b 28/22 31/39 0.140b
Age [years] 47.9  7.0 45.0  7.2 0.030 48.9  7.3 45.4  6.8 0.005
BMI [kg/m2] 32.2  1.9 32.0  2.1 0.701 31.3  1.9 29.8  2.4 0.001
WC [cm] 108  7.3 103  8.1 <0.001 105  7.8 98.3  7.3 <0.001
SBP [mmHg] 141  14 134  15 0.002 137  15 124  14 <0.001
DBP [mmHg] 95  11 91  12 0.093 92  11 85  11 <0.001
TC [mg/dl] 247  44.6 230  41.1 0.048 247  46.5 224  41.2 0.010
HDL-C [mg/dl] 50.2  10.2 62.0  11.5 <0.001 52.2  10.2 56.0  12.3 0.147
TG [mg/dl] 209  130.9 114  48.2 <0.001 198  109 120  64.8 <0.001
Glucose [mg/dl] 99.1  13.9 90.3  6.3 <0.001 102  14.9 89.4  7.7 <0.001
aMann-Whitney U test, bchi-square test. 
 
Table 3. Subjects’ characteristics according to the number of criteria of the metabolic syndrome fulfilled at baseline and after 
twelve weeks (n = 120). 
No. of criteria fulfilled 0 1 2 3 4 5 
Baseline       
N 0 8 36 46 26 4 
BMI [kg/m2] - 31.1  2.0 32.2  2.0 32.1  1.9 31.9  1.9 34.1  1.0* 
WC [cm] - 105  5.1 102  8.6 107  7.5** 109  6.9 111  6.6 
SBP [mmHg] - 125  6.1 136  16.2* 140  12.7 145  17.1 136  10.2 
DBP [mmHg] - 81.9  6.9 93.3  11.7** 94.1  10.0 96.8  12.2 91.9  6.8 
HDL-C [mg/dl] M - 52.6  4.9 60.0  13.2 49.9  8.0* 47.1  11.7* 35.3  3.1* 
HDL-C [mg/dl] F - 63.3  18.8 63.6  10.7 56.3  9.7* 49.0  7.3* 42.0 
TG [mg/dl] - 101  22.8 117  52.0 165  74.2** 283  176*** 241  94.5 
Glucose [mg/dl] - 90.4  6.0 90.2  6.4 95.0  10.0* 105  17.8* 110  1.7 
12 weeks       
N 4 23 43 37 13 0 
BMI [kg/m2] 27.9  1.4 28.9  2.1 30.5  2.5* 31.1  1.9 31.9  1.9 - 
WC [cm] 94.8  3.9 95.7  6.4 100  7.5 105  8.2** 106  6.4 - 
SBP [mmHg] 115  7.6 117  11.7 129  13.6** 134  14.7 142  13.7 - 
DBP [mmHg] 77.3  4.5 79.8  9.3 88.6  11.4** 92.4  11.0 92.3  10.3 - 
HDL-C [mg/dl] M 58.0  5.3 51.8  12.5 50.1  13.4 50.4  11.1 51.0  11.8 - 
HDL-C [mg/dl] F 83.0 60.2  10.4 56.5  9.5 55.4  9.2 49.2  2.6 - 
TG [mg/dl] 92.3  24.6 96.9  29.1 135  76.3* 167  66.9** 286  153** - 
Glucose [mg/dl] 85.5  5.8 87.1  8.3 91.1  7.2 97.7  9.6*** 112  21.4** - 
M  : male; F: female; 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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Table 4. Correlations (Spearman correlation coefficients) of 
changes in body weight and BMI with the changes in sev- 
eral variables of the metabolic syndrome in the total study 
group (n = 120). 
Variables 
Change in 
 
12 0t -t
weight p 
Change in 
 
12 0t -t
BMI p 
Weight - - 0.981 <0.001
BMI 0.981 <0.001 - - 
WC 0.756 <0.001 0.761 <0.001
SBP 0.403 <0.001 0.410 <0.001
DBP 0.389 <0.001 0.385 < 0.001
TC 0.236 0.009 0.236 <0.010
HDL-C −0.134 0.144 −0.100 0.278
TC/HDL-C 
ratio 0.360 <0.001 0.339 <0.001
TG 0.324 <0.001 0.310 0.001
Glucose 0.264 0.004 0.273 0.003
SCOREa 0.274 0.007 0.247 0.016
an = 95, age ≥ 40 years. 
 
Table 5. Characteristics of the SCORE subgroup aged ≥ 40 
years at baseline and after twelve weeks (n = 95). 
Parameter Baseline 12 weeks pa 
SCORE [%] 1.88  0.19 1.58  0.16 <0.001
 (range: 0 - 11) (range: 0 - 9)  
Subjects at high risk [%] 7.4 (n = 7) 5.3 (n = 5) 0.500b
BMI [kg/m2] 32.2  1.9 30.5  2.3 <0.001
WC [cm] 107  7.8 102  8.1 <0.001
SBP [mmHg] 139  14 130  15 <0.001
DBP [mmHg] 94  11 88  11 <0.001
TC [mg/dl] 246  44.9 237  45.7 0.006
HDL-C [mg/dl] 55.3  11.2 55.4  10.6 0.942
TC/HDL-C ratio 4.6  1.0 4.4  1.0 0.001
TG [mg/dl] 173  93.3 154  88.1 <0.001
Glucose [mg/dl] 97.5  12.5 95.9  13.5 0.018
aWilcoxon test, bMcNemar chi-square test. 
 
variables, such as the TC/HDL-C ratio (r = 0.359, p < 
0.001) and SBP (r = 0.403, p < 0.001). We also found 
significant relations between the changes in SCORE and 
changes in other traditional CV risk factors, such as TC 
(r = 0.319, p < 0.01), LDL-C (r = 0.260, p < 0.05), LDL- 
C/HDL-C ratio (r = 0.311, p < 0.01), TG (r = 0.377, p < 
0.001), and WC (r = 0.294, p < 0.01). At baseline and 
after twelve weeks, age had the strongest correlation with 
the CV risk SCORE (t0: r = 0.674, p < 0.001; t12: r = 
0.655, p < 0.001). 
3.3. Intersection of Risk SCORE and Metabolic 
Syndrome 
In the SCORE subgroup with an age of 40 and above, n = 
64 (67.4%) of the subjects had a metabolic syndrome at 
baseline. This proportion decreased after twelve weeks to 
n = 44 (46.3%). There was a reduction in the number of 
subjects (n = 24) without metabolic syndrome, while n = 
4 subjects developed it after twelve weeks. The differ- 
ence between upgrading and worsening was highly sig- 
nificant (p < 0.001). 
The CV risk SCORE was significantly higher in sub- 
jects with the metabolic syndrome than in subjects with- 
out the metabolic syndrome both at baseline and at the 
end of the study (Table 6).  
Additionally, we compared the incidence of the meta- 
bolic syndrome with the individuals identified as high 
risk. The percentage of subjects at high risk (SCORE ≥ 
5%) decreased from 7.4% (n = 7) at baseline to 5.3% (n 
= 5) after the intervention. At baseline, six out of seven 
individuals with a SCORE ≥ 5% (high risk) also had a 
metabolic syndrome. After twelve weeks, three out of 
five high risk patients were also identified with a meta- 
bolic syndrome, whereas two individuals at high risk did 
not have a metabolic syndrome. 
4. Discussion 
Obesity in men and women is associated with a higher 
prevalence of the metabolic syndrome and CVD [21]. It  
 
Table 6. Comparison of the risk SCORE in subjects with 
and without the metabolic syndrome in the SCORE sub- 
group aged ≥ 40 years at baseline and after twelve weeks (n 
= 95). 
 
With  
metabolic  
syndrome 
Without  
metabolic  
syndrome 
pa 
baseline    
N 64 31  
SCORE [%] 2.18  2.05 0.97  1.11 <0.001
Subjects at high risk 
[n] 6 1  
12 weeks    
N 44 51  
SCORE [%] 1.92  1.85 1.04  1.2 0.002
Subjects at high risk 
[n] 3 2  
aMann-Whitney U test. 
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is estimated that, depending on the corresponding defini- 
tion, ethnicity and country, 20% - 35% of the adult popu- 
lation are affected by a metabolic syndrome [4,22,23]. 
Results from a cross-sectional study on the prevalence 
and regional distribution of the metabolic syndrome in 
primary care practices in Germany showed an age-stan- 
dardized prevalence of the metabolic syndrome of 19.8% 
(22.7% in men and 18.0% in women) [24,25]. The crite- 
ria of the metabolic syndrome were exactly the same 
criteria that were used in our study. The prevalence of the 
metabolic syndrome in this study population at baseline 
was 63%. While, in accordance with Moebus et al. 2008, 
men were significantly more often concerned than 
women, the overall prevalence in our study was almost 
three times higher. A former interventional trial with 185 
obese individuals showed a comparable initial prevalence 
of 68% [15]. 
According to numerous experts, weight loss is of pri- 
mary importance for the management of the metabolic 
syndrome [4,19,26]. Studies have shown that a moderate 
weight loss and lifestyle modifications are effective for 
improving several components of the metabolic syn- 
drome [15,16,27,28]. Results of our study demonstrated 
that a 12-week weight reduction programme reduces sin- 
gle aspects of the metabolic syndrome and the overall 
prevalence of the metabolic syndrome as well. In this 
context, weight loss was statistically significant related to 
the changes in components of the metabolic syndrome 
(Table 4). The majority of the metabolic syndrome vari- 
ables improved in response to this intervention (Table 2). 
The highest improvements after weight loss were seen in 
the variables WC and blood pressure. These two factors 
have also been shown to be most frequent in men and 
women with metabolic syndrome [29]. 
The clustering of risk factors and the obvious im- 
provement with weight reduction and correlation to weight 
change support the hypothesis that obesity plays a central 
role in the pathogenesis of this syndrome [15]. 
In contrast to the high prevalence of the metabolic 
syndrome in this study, the average 10-year CV risk of 
all study participants investigated was 1.88%  0.19% 
and could be considered as quite low. As expected, the 
SCORE value was significantly higher in men than in 
women. Although the baseline 10-year CV risk was low, 
there was a highly significant improvement during inter- 
vention in men, women and in the total study group. The 
decrease in this CV risk SCORE could be connected with 
the weight loss and changes in BMI (Table 4). The per- 
centage of individuals at high risk (SCORE ≥ 5%) was 
low (7.4%) as well, and did not change remarkably. Cur- 
rently, comparative data related to risk SCORE assess- 
ment from a German population group is rare. The CV 
risk SCORE was assessed in a nationwide cross-sectional 
point prevalence study with a sample of unselected pa- 
tients (n = 10,323 men, n = 18,852 women, aged 35 - 65 
years). The prevalence of patients that had a low SCORE 
risk (10-year risk < 5%) in relation to the waist circum- 
ference was 76% - 89% in men and 97% - 99% in 
women [30]. In this study, a low SCORE risk (10-year 
risk < 5%) was evaluated in 92.6% of the subjects at 
baseline and in 94.7% after twelve weeks of intervention.  
However, in a cohort of 7641 primary care outpatients 
aged ≥ 50 years with no CV disease, 57.1% of German 
patients (38.4% of European patients) overall were con- 
sidered to be at high CV risk based on a SCORE total of 
≥ 5% [14]. In this connection, it was claimed that there 
might be an overestimation of CV risk predicted by the 
SCORE risk function in European populations [14,31, 
32]. 
It must be pointed out that there might be limitations 
for the use of the German risk charts for this collective 
presented and in this investigation. Looking at the sub- 
jects’ characteristics at the beginning of the study, in- 
cluding the grade of obesity and the significantly ele- 
vated parameters, such as WC, SBP, DBP, TC, and TG, 
it seems obvious that the SCORE values underestimated 
the 10-year CV risk of the subjects assessed. It should be 
noted that the overall risk in obese people in the guidance 
of the SCORE tables may be higher than indicated in the 
calculations. It is merely a note that is not backed by an 
actual value. We have to assume, however, that the ac- 
tual extent of the CV risk in this collective is considera- 
bly higher.  
In light of the risk SCORE model, the database of the 
European Heartscore project has to be considered. The 
SCORE database only includes fatal endpoints (e.g. car- 
diac death). This means a smaller sample size and, con- 
sequently, lower 10-year risks. The limitation of the 
SCORE project on CV mortality is based on the fact that 
standardized data for this endpoint are updated constantly 
and are available at each regional level. This does not 
apply to data on morbidity. 
Although the CV risk SCORE might be underesti- 
mated in the current calculations, it is frequently used in 
clinical practice. In a multinational, cross-sectional study 
in twelve European countries (EURIKA), 58.3% of all 
German and 52.0% of all European physicians used the 
global risk SCORE most commonly [14]. 
The metabolic syndrome is characterized by the com- 
mon occurrence of abdominal obesity, hypertension, 
dyslipidemia, and hyperglycaemia as an expression of 
insulin resistance [33]. The presence of the metabolic 
syndrome confers an increased risk for type 2 diabetes 
mellitus and CVDs [9,34]. It was, therefore, possible to 
demonstrate in the present study that the CV risk SCORE 
calculated was increased in patients with metabolic syn- 
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drome (Table 6). An increased CV risk was observed in 
patients with the metabolic syndrome in other studies as 
well [35]. 
In contrast to the results of the SCORE calculation, the 
diagnosis of the metabolic syndrome gave clearer infor- 
mation about the extent of a cardiometabolic risk within 
the collective investigated. This difference possibly re- 
sults from the fact that the criteria of the metabolic syn- 
drome (WC, DBP and fasting glucose) are not considered 
in the risk SCORE. The combination of risk factors of 
metabolic syndrome, therefore, leads to a different as- 
sessment of CV risk [36]. 
According to the NCEP ATP-III (2002), risk scores 
such as SCORE or Framingham risk score were devel- 
oped for assessing CV risk in the short-term (≤10 years), 
whereas identification of individuals with the metabolic 
syndrome is needed for long-term CV and metabolic risk 
assessment [19,36]. 
5. Conclusion 
The metabolic syndrome was present in over two-thirds 
of overweight and obese subjects enrolling in this weight 
reduction intervention. A moderate weight loss over twelve 
weeks led to an improvement of all components of the 
metabolic syndrome. Weight loss, therefore, was associ- 
ated with the changes in each of the factors of the meta- 
bolic syndrome. Whereas the occurrence of the metabolic 
syndrome in this study was high, the average CV risk 
SCORE was comparatively low. However, there was 
again a significant improvement during intervention in 
the study population. The CV risk SCORE might be un- 
derestimated in the current calculations. In sum, the di- 
agnosis of a metabolic syndrome was more meaningful 
than risk SCORE calculations. 
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